

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

### Thursday, 9 October 2025

13:00 – 14:00

#### **Session I: Pathogenesis of acquired AA**

**Chairs:** *Ted Gordon-Smith (UK) & Andrea Bacigalupo (IT)*

13:00 – 13:20

From a genetic point of view

Marcin Wlodarski (DE)

13:20 – 13:40

From an immunology point of view

Leo Hansmann (DE)

13:40 – 14:00

HLA and AA: Friends or Foe

14:00 – 15:30

#### **Session II: 30 years in AA – What have we learned**

**Chairs:**

14:00 – 14:20

Diagnosis

Alicia Rovó (CH)

14:20 – 14:40

Treatment I: Transplantation

Andrea Bacigalupo (IT)

14:40 – 15:00

Treatment II: IST

Jakob Passweg (CH)

15:00 – 15:20

Late effects

15:20 – 15:30

Discussion: What have learned in 30 years

15:30 – 16:00

#### **Coffee Break**

16:00 – 16:45

#### **Industry Symposium Slot**

16:45 – 17:45

#### **Session III: Inherited BMFs: HCT Versus gene therapy**

**Chairs:** *Carlo Dufour (IT) & Constantijn Halkes (NL)*

16:45 – 17:05

Role of HCT in inherited BMFs

Éliane Gluckman (FR)

17:05 – 17:25

Gene Therapy in inherited BMFs

17:25 – 17:45

Genetic counselling of families (patients and donor!) with inherited BMFs

20:00 – 22:00

#### **Scientific Business Meeting**

Friday, 10 October 2025

09:00 – 10:00	<b>Session IV: Complement</b> <b>Chairs:</b> <i>Camilla Frieri (IT) &amp; Jaroslaw Maciejewski (US)</i>	
09:00 – 09:20	Complement and disease	
09:20 – 09:40	Other complement – associated diseases / Benefits of complement inhibitors in other indications	
09:40 – 10:00	Discussion: complement and transplant/more	
10:00 – 11:00	<b>Session V: Daily hurdles in AA</b> <b>Chairs:</b> <i>Olaia Naveiras (CH)</i>	
10:00 – 10:20	Tapering EPAG – How, when and when to re-start again...	Beatrice Drexler (CH)
10:20 – 10:34	Work up and treatment of MAA (Results of EMAA)	Britta Höchsmann (DE)
10:40 – 11:00	How to distinguish “clonal haematopoiesis” from “transformation” in AA	Daria Babushok (US)
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 12:45	<b>Session VI: Initiative session</b> <b>Chairs:</b>	
11:30 – 11:55	ICARIIS initiative	
11:55 – 12:20	AA treatment decisions/algorithm	Rodrigo Calado (BR)
12:20 – 12:45	Status of art: HCT versus IST (SAAWP initiatives)	
12:45 – 13:30	<b>Lunch Break</b>	
13:30 – 14:15	<b>Industry Symposium kindly sponsored by Novartis</b>	
14:15 – 15:30	<b>Session VII: PNH</b> <b>Chairs:</b>	
14:15 – 14:35	Therapeutic algorithm in 2025 for PNH	Morag Griffin (UK)
14:35 – 14:55	HSCT in PNH	Camilla Frieri (IT)
14:55 – 15:15	Future directions in PNH	
15:15 – 15:30	Discussion	
15:30 – 16:00	<b>Coffee Break</b>	
16:00 – 17:15	<b>Session VIII: The patients, the nurses and caregivers perspective</b> <b>Chairs:</b> <i>Britta Hochsmann (DE)</i>	
16:00 – 16:25	Deciphering fatigue in AA/PNH for future care	Pascale Burmester (DE)
16:25 – 16:50	Transition of AA patients	
16:50 – 17:15	Infectious risk in AA patients	

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

### Saturday, 11 October 2025

#### 09:00 – 10:00 **Session IX: Deciphering acquired versus inherited BMFs in 2025**

**Chairs:** *Maurizio Miano (IT) & Alicia Rovo (CH)*

09:00 – 09:20 From the pediatric perspective

09:20 – 09:40 From the adults perspective

09:40 – 10:00 New germline kids on the block in 2025

Carlo Dufour (IT)

Simone Feurstein (DE)

Marcin Wlodarski (DE)

#### 10:00 – 11:00 **Session X: Long-term outcome**

**Chairs:**

10:00 – 10:20 Long term outcome in IST versus HCT

10:20 – 10:40 How to follow up on inherited BMF to detect “transformation”

10:40 – 11:00 How to follow up on QoL in AA?

Beatrice Drexler (CH)

Fabian Beier (DE)

#### 11:00 – 11:30 **Coffee Break**

#### 11:30 – 12:30 **Session XI: Future Directions**

**Chairs:** *Beatrice Drexler (CH)*

11:30 – 11:50 Finding the individual trigger in acquired AA

11:50 – 12:10 New kids on the block (Ruxo, Tregs, ...)

12:10 – 12:30 Machine learning & artificial intelligence in the diagnosis and risk stratification of AA

Jaroslawn Maciejewski (US)

Shreyans Gandhi (UK)